Bioneer Corporation (KOSDAQ:064550)
South Korea · Delayed Price · Currency is KRW 6,860.00
+50.00 (0.73%)
Nov 2, 2026, 3:30 PM KST
Bioneer Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 345,882 | 330,111 | 293,975 | 263,237 | 218,394 | 223,744 |
Revenue Growth | 15.87% | 12.29% | 11.68% | 20.53% | -2.39% | 8.09% |
Gross Profit Gross Profit Growth | 264,992 | 256,794 | 219,489 | 202,500 | 166,072 | 173,216 |
Operating Income Operating Income Growth | 6,235 | 15,225 | -13,415 | 772.7 | 10,744 | 47,066 |
Net Income Net Income Growth | -6,673 | -2,813 | -20,584 | -10,587 | 12,077 | 27,160 |
Earnings Per Share EPS Growth | -258.54 | -108.99 | -797.52 | -410.19 | 467.91 | 1073.00 |
EPS Growth | - | - | - | - | -56.39% | -55.40% |
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Research and Molecular Diagnostics Research and Molecular Diagnostics Growth | 40,670 | 38,776 | 39,362 |
Probiotics Probiotics Growth | 321,532 | 307,140 | 268,806 |
RNAi new Drug Development RNAi new Drug Development Growth | 2,101 | 2,404 | 705.56 |
Inter Segment Elimination Inter Segment Elimination Growth | -18,422 | -18,208 | -14,898 |
Total Total Growth | 345,882 | 330,111 | 293,975 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 86,283 | 92,512 | 94,259 | 91,833 | 80,035 | 82,627 |
Total Debt Total Debt Growth | 106,581 | 106,410 | 73,721 | 44,640 | 27,870 | 21,021 |
Net Cash (Debt) Net Cash Growth | -20,299 | -13,898 | 20,538 | 47,193 | 52,165 | 61,606 |
Net Cash Growth | - | - | -56.48% | -9.53% | -15.33% | 32.21% |
Net Cash Per Share Net Cash Per Share Growth | -786.46 | -538.47 | 795.72 | 1828.46 | 2021.08 | 2434.75 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -4,540 | 10,331 | -13,476 | 4,136 | 8,805 | 53,175 |
Capital Expenditures CapEx Growth | -5,117 | -48,011 | -12,635 | -4,660 | -17,460 | -42,177 |
Free Cash Flow Free Cash Flow Growth | -9,656 | -37,679 | -26,111 | -523.93 | -8,655 | 10,998 |
Free Cash Flow Growth | - | - | - | - | - | -73.30% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 76.61% | 77.79% | 74.66% | 76.93% | 76.04% | 77.42% |
Operating Margin | 1.80% | 4.61% | -4.56% | 0.29% | 4.92% | 21.04% |
Pretax Margin | 0.95% | 3.00% | -5.21% | -0.03% | 6.37% | 19.34% |
Profit Margin | -1.93% | -0.85% | -7.00% | -4.02% | 5.53% | 12.14% |
FCF Margin | -2.79% | -11.41% | -8.88% | -0.20% | -3.96% | 4.92% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 62.83 | 46.19 |
Forward PE | - | 7.58 | 12.14 | 4.41 | 4.41 | 4.41 |
P/FCF Ratio | - | - | - | - | - | 114.06 |
PS Ratio | 0.51 | 1.00 | 1.66 | 3.27 | 3.48 | 5.61 |